The global migraine treatment market is anticipated to achieve a valuation of USD 3.2 billion in 2023 and is expected to grow to approximately USD 4.74 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4% during the forecast period from 2023 to 2033. The market demonstrated a steady growth rate of 3% in the historical period from 2018 to 2022.
The rising prevalence of migraines and increasing awareness about effective treatment options are significant drivers behind the growth of the migraine treatment market. As awareness of migraine as a chronic condition continues to expand, patients are more likely to seek treatment, thereby increasing demand for various therapeutic options.
Advancements in migraine therapies, including new medications and innovative treatment protocols, are also contributing to market growth. The introduction of preventive treatments and personalized medicine approaches is expected to enhance patient outcomes and satisfaction, further fueling market expansion.
North America currently dominates the migraine treatment market, supported by a well-established healthcare system, significant investment in research and development, and high patient awareness. Meanwhile, the Asia-Pacific region is emerging as a high-growth area, driven by rising healthcare expenditures, increasing access to treatment options, and growing patient education initiatives.
As the demand for effective migraine treatments continues to rise, industry players are expected to focus on research and innovation, developing new therapies, and improving access to existing treatments. The future of the migraine treatment market looks promising, with opportunities for enhanced patient care and improved quality of life for individuals suffering from migraines.
Which are Some Prominent Drivers of the Migraine Treatment Market?
Growing advancements in diagnostic and treatment options to push the market growth
The global Migraine Treatment market is primarily driven by an increased prevalence of Migraine, which is driving the demand for effective treatments. According to the Migraine Research Foundation, migraine is the third most common disease in the world, affecting an estimated 1 billion people globally. This large patient population represents a significant market opportunity for companies developing migraine treatments.
In recent years, there has been a growing focus on developing targeted therapies that can provide more effective and personalized treatment for migraine patients. For example, new monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be highly effective in preventing migraines in some patients.
Additionally, the growth of the Migraine Treatment market is owed to ongoing research and development, which is leading to an increased potential for new and improved treatment options to become available for patients with Migraine. There is a growing investment in research and development of treatments for Migraine, with many biotech and pharmaceutical companies working on developing new gene therapies for these conditions.
For instance, in February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
Market Competition
Key players in the market include companies such as Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Allergan, Teva Pharmaceuticals, Biohaven Pharmaceuticals, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., and Charleston Laboratories, along with healthcare providers and technology companies among other global players.
- In January 2022, BioDelivery Sciences launched a new drug, Elyxyb (celecoxib oral solution), a fast-acting liquid. It is one of the first Food and Drug Administration-approved ready-to-use oral solutions for adults in the acute treatment of migraine, with or without aura.
- In September 2021, AbbVie received FDA approval for QULIPTA™ (atogepant), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically designed to prevent episodic migraine in adults. QULIPTA is an oral medication that can help reduce monthly migraine days with a once-daily dosage that works quickly and continuously. AbbVie is proud to offer three products for the complete spectrum of migraine treatment, including preventive therapies for chronic and episodic migraine and an acute treatment for migraine attacks. This approval is backed by a clinical program that evaluated the safety, tolerability, and effectiveness of QULIPTA in almost 2,000 patients who experienced 4 to 14 migraine days per month, including the Phase 3 ADVANCE study, the Phase 2b/3 study, and the Phase 3 long-term safety study.
Key Companies Profiled
Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Allergan, Teva Pharmaceuticals, Biohaven Pharmaceuticals, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., and Charleston Laboratories
Key Segments Profiled in the Migraine Treatment Industry Survey
Drug Class:
- Zavegepant
- Atogepant
- Zolmitriptan
Route of Administration:
- Oral
- Parenteral
- Nasal Sprays
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Treatment:
- Abortive Medicine
- Preventive Medicine
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube